Synthetic Biology

A Complete List of 27 Gene Editing Stocks

Synthetic biology is the single most exciting technology we know of, but execution has been problematic. From Intrexon to Zymergen, synthetic biology stocks have punished investors for believing that harnessing the most powerful technology known to man – nature – was going to be easy. While we couldn’t be more excited about the potential of […]

Why Ginkgo Bioworks Stock Soared Yesterday

Admittedly, this is a clickbait title. Nobody is capable of deciphering why stocks move the way they do which is why hedge funds are now dominated by algorithms with a vociferous appetite for big data. However, we do know two things are true – Ginkgo Bioworks released their 10-K annual report yesterday, and the stock […]

Amyris Stock: Putting Lipstick on a Pig

Synthetic biology is probably the single most exciting technology theme we cover. Nature is the most powerful technology known to man, and we’re not only on the cusp of harnessing it but making it better by using technologies like gene editing. But for investors, synbio has been anything but exciting. Over four years ago, we […]

Codexis Stock: A Risky Play on Enzymes

A great interview question to ask a fresh-faced MBA goes something like this. “Take the most sophisticated financial concept you know and explain it to me like I’m your grandmother.” It’s an elegant way to find out just how well a candidate understands the dreadfully boring financial concepts they’re forced to memorize, while simultaneously probing […]

Challenges Ahead for Twist Bioscience Stock

There’s always a delicate balance between being too hands on with a stock and not paying close enough attention to how its business evolves. Revenue growth is the one metric that cuts through all the noise and distills it down to what’s most important for a disruptive technology stock. Is a company able to monetize […]

Ginkgo Bioworks Responds to Short Seller Report

Pumping and dumping a stock is illegal. Perhaps the most entertaining – and extremely accurate – portrayal of stock promotion was the movie Boiler Room in which a bunch of BSDs fleece the middle class before finally getting taken down by the SEC. Today, pumping seems to be the cool thing to do. Meme stocks […]

Ginkgo Bioworks Stock Just Got a Whole Lot Riskier

One thing you learn in risk management class is that risk can be defined as the volatility of returns. It’s a way of not thinking about up or down, but rather the stability of a stock price. From that you can infer that stable stock prices are more desirable. So, when volatility gets introduced to […]

Why We’re Selling Berkeley Lights Stock

If you decide to bare your investing decisions for the world to see, you better do so with conviction. Unless your thesis changes, you should never sell a stock. When additional information becomes available that threatens your thesis, you ought to examine it objectively and act accordingly. That’s why when activist short-seller Scorpion Capital released […]

4 Companies Replacing Nitrogen in Fertilizers

In our recent profile on Motif FoodWorks, we described how the company is turning microbes into biological factories to produce specialized proteins to enhance the production, taste, and texture of plant-based food. It’s only one example of how synthetic biology may someday disrupt our entire food system. Today we’re going to focus on where it […]

Cytek Biosciences Stock – A Play on Flow Cytometry

Physicist Richard Feynman’s famous talk “There’s Plenty of Room at the Bottom” proposed that mankind would eventually get around to creating things at a cellular level, and it looks like we’ve started down that path. The single-cell revolution is here, with about a dozen life sciences companies offering technology platforms for working with cells. Today, […]